PTK2 and cancer: Another example is BSJ-04–146, a PROTAC-based inhibitor that not only blocks the kinase activity but also degrades the FAK protein itself, leading to better control over cancer cell migration in lab tests compared to traditional inhibitors like Defactinib8.